T1	Procedure 0 12	Histological
T2	Value 13 25	confirmation
T3	Condition 63 78	B-cell lymphoma
T4	Qualifier 57 62	large
T5	Qualifier 49 56	diffuse
R1	Has_qualifier Arg1:T3 Arg2:T4	
R2	Has_qualifier Arg1:T3 Arg2:T5	
T7	Procedure 91 156	rituximab and anthracycline-containing systemic treatment regimen
T8	Drug 165 171	R-CHOP
T9	Drug 173 182	rituximab
T10	Drug 184 200	cyclophosphamide
T11	Drug 202 213	doxorubicin
T12	Drug 215 226	vincristine
T13	Drug 232 242	prednisone
T14	Scope 173 242	rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone
R3	Subsumes Arg1:T8 Arg2:T14	
T15	Drug 245 252	R-EPOCH
T16	Drug 254 263	rituximab
T17	Drug 265 284	etoposide phosphate
T18	Drug 286 296	prednisone
T19	Drug 298 317	vincristine sulfate
T20	Drug 319 335	cyclophosphamide
T21	Drug 337 362	doxorubicin hydrochloride
T22	Scope 254 362	rituximab, etoposide phosphate, prednisone, vincristine sulfate, cyclophosphamide, doxorubicin hydrochloride
R4	Subsumes Arg1:T15 Arg2:T22	
T23	Drug 365 376	R-HyperCVAD
T24	Drug 378 387	rituximab
T25	Drug 389 405	cyclophosphamide
T26	Drug 407 426	vincristine sulfate
T27	Drug 428 453	doxorubicin hydrochloride
T28	Drug 455 468	dexamethasone
T29	Scope 378 468	rituximab, cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, dexamethasone
R5	Has_scope Arg1:T23 Arg2:T29	
R6	Has_value Arg1:T1 Arg2:T2	
T6	Drug 91 100	rituximab
T30	Drug 105 118	anthracycline
T31	Scope 165 473	R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), R-EPOCH (rituximab, etoposide phosphate, prednisone, vincristine sulfate, cyclophosphamide, doxorubicin hydrochloride), R-HyperCVAD (rituximab, cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, dexamethasone) etc
R7	Subsumes Arg1:T7 Arg2:T31	
T32	Temporal 79 84	after
T33	Reference_point 85 156	prior rituximab and anthracycline-containing systemic treatment regimen
R8	Has_index Arg1:T32 Arg2:T33	
R9	Has_temporal Arg1:T1 Arg2:T32	
R10	AND Arg1:T1 Arg2:T3	
T34	Multiplier 504 518	no more than 2
T35	Temporal 519 524	prior
T36	Procedure 525 556	systemic therapies for lymphoma
R11	Has_temporal Arg1:T36 Arg2:T35	
R12	Has_multiplier Arg1:T36 Arg2:T34	
T37	Drug 586 595	rituximab
T38	Procedure 577 585;596 607	systemic monotherapy
R13	AND Arg1:T38 Arg2:T37	
T39	Temporal 558 563	Prior
T40	Procedure 611 636	conventional chemotherapy
T41	Drug 643 655	bendamustine
T42	Drug 657 660	CVP
T43	Drug 662 678	Cyclophosphamide
T44	Drug 680 699	Vincristine Sulfate
T45	Drug 701 711	Prednisone
T46	Scope 662 711	Cyclophosphamide, Vincristine Sulfate, Prednisone
R14	Subsumes Arg1:T42 Arg2:T46	
*	OR T41 T42
T47	Drug 725 734	rituximab
A1	Optional T47
T48	Condition 748 776	non-Hodgkin's lymphoma (NHL)
T49	Qualifier 739 747	indolent
R15	Has_qualifier Arg1:T48 Arg2:T49	
T50	Drug 804 813	rituximab
*	OR T38 T40
T51	Scope 643 721	bendamustine, CVP (Cyclophosphamide, Vincristine Sulfate, Prednisone) or other
R16	Subsumes Arg1:T40 Arg2:T51	
R17	AND Arg1:T47 Arg2:T48	
A2	Optional T50
T52	Qualifier 779 790	maintenance
T53	Qualifier 791 803	extended-use
*	OR T53 T52
T54	Scope 779 803	maintenance/extended-use
R18	Has_scope Arg1:T50 Arg2:T54	
T55	Measurement 857 917	Eastern Cooperative Oncology Group (ECOG) Performance status
T56	Value 918 921	≤ 2
R19	Has_value Arg1:T55 Arg2:T56	
T57	Condition 942 954;966 974	normal organ function
T58	Condition 942 948;959 974	normal marrow function
*	OR T58 T57
T59	Scope 923 992	Subjects must have normal organ and marrow function as defined below:
T60	Measurement 994 1004	Hemoglobin
T61	Value 1005 1015	≥ 8.0 g/dl
R20	Has_value Arg1:T60 Arg2:T61	
T62	Measurement 1017 1042	Absolute neutrophil count
T63	Value 1043 1054	≥ 1,000/mcL
R21	Has_value Arg1:T62 Arg2:T63	
T64	Measurement 1056 1070	Platelet count
T65	Value 1071 1083	≥ 75,000/mcL
R22	Has_value Arg1:T64 Arg2:T65	
T66	Measurement 1085 1100	Total bilirubin
T67	Value 1101 1140	≤ 1.5 X the upper limit of normal (ULN)
T68	Condition 1167 1197	impaired bilirubin conjugation
T69	Condition 1206 1215	Gilbert's
R24	Subsumes Arg1:T68 Arg2:T69	
T70	Value 1230 1237;1246 1253	maximum 2.5 ULN
*	OR T67 T70
R23	AND Arg1:T70 Arg2:T68	
T71	Scope 1101 1253	≤ 1.5 X the upper limit of normal (ULN) unless a known history of impaired bilirubin conjugation such as Gilbert's, for whom the maximum will be 2.5 ULN
R25	Has_scope Arg1:T66 Arg2:T71	
T72	Measurement 1256 1291	Aspartate transaminase (AST) (SGOT)
T73	Value 1292 1317	≤ 2.5 X institutional ULN
R26	Has_value Arg1:T72 Arg2:T73	
T74	Measurement 1319 1352	Alanine transaminase (ALT) (SGPT)
T75	Value 1353 1378	≤ 2.5 X institutional ULN
R27	Has_value Arg1:T74 Arg2:T75	
T76	Measurement 1380 1416	International normalized ratio (INR)
T77	Value 1417 1427	> 1.5 ×ULN
R28	Has_value Arg1:T76 Arg2:T77	
T78	Measurement 1461 1487	serum creatinine clearance
T79	Value 1488 1499	> 50 mL/min
R29	Has_value Arg1:T78 Arg2:T79	
T80	Qualifier 1506 1533	Cockcroft-Gault calculation
T81	Qualifier 1546 1570	24-hour urine collection
T82	Temporal 1581 1600	within 7 days prior
T83	Reference_point 1604 1613	treatment
R30	Has_index Arg1:T82 Arg2:T83	
*	OR T80 T81
T84	Scope 1506 1570	Cockcroft-Gault calculation or based on 24-hour urine collection
R31	Has_scope Arg1:T78 Arg2:T84	
R32	Has_temporal Arg1:T78 Arg2:T82	
T85	Parsing_Error 1616 1753	Specific guidelines will be followed regarding inclusion of relapsed/refractory DLBCL based on Hepatitis B serological testing as follow:
T86	Measurement 1755 1760	HBsAg
T87	Value 1761 1769	negative
T88	Measurement 1771 1776	HBcAb
T89	Value 1777 1785	negative
R33	Has_value Arg1:T86 Arg2:T87	
R34	Has_value Arg1:T88 Arg2:T89	
T90	Measurement 1787 1792	HBsAb
T91	Value 1793 1801	positive
R35	Has_value Arg1:T90 Arg2:T91	
T92	Measurement 1857 1862	HBsAg
T93	Value 1844 1852	positive
R36	Has_value Arg1:T92 Arg2:T93	
T94	Grammar_Error 1863 1877	are ineligible
T95	Measurement 1893 1898	HBsAg
T96	Value 1899 1907	negative
R37	Has_value Arg1:T95 Arg2:T96	
T97	Measurement 1913 1918	HBcAb
T98	Value 1919 1927	positive
R38	Has_value Arg1:T97 Arg2:T98	
T99	Procedure 1971 1986	HBV DNA testing
T100	Parsing_Error 1879 2042	Patients with HBsAg negative, but HBcAb positive (regardless of HBsAb status) should have a HBV DNA testing performed and protocol eligibility determined as follow
T101	Measurement 2048 2055	HBV DNA
T102	Value 2059 2067	positive
R39	Has_value Arg1:T101 Arg2:T102	
T103	Grammar_Error 2045 2094	If HBV DNA is positive, the subject is ineligible
T104	Measurement 2100 2107	HBV DNA
T105	Value 2111 2119	negative
R40	Has_value Arg1:T104 Arg2:T105	
T106	Non-query-able 2153 2242	must undergo HBV DNA PCR testing monthly x 3 months beginning from the start of treatment
T107	Non-query-able 2244 2352	Subjects must have the ability to understand and the willingness to sign a written informed consent document
T108	Post-eligibility 2355 2683	For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use a contraceptive method with a failure rate of < 1% per year during the treatment period and for at least 30 days after the last dose of venetoclax or 18 months after the last dose of rituximab, whichever is longer.
T109	Not_a_criteria 2685 2969	A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state (< 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus)
T110	Parsing_Error 2972 3145	For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as defined below:
T111	Non-query-able 2972 3145	For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as defined below:
T112	Post-eligibility 2972 3144	For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as defined below
T113	Post-eligibility 3147 3420	With female partners of childbearing potential, men must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of < 1% per year during the treatment period and for at least 6 months after the last dose of rituximab.
T115	Non-query-able 3421 3482	Men must refrain from donating sperm during this same period.
T116	Non-query-able 3484 3673	With pregnant female partners, men must remain abstinent or use a condom during the treatment period and for at least 6 months after the last dose of rituximab to avoid exposing the embryo.
